Disclaimers & References

1. Data on file, Abbott Diabetes Care, Inc. Based on the number of users worldwide for the FreeStyle Libre portfolio compared to the number of users for other leading personal use sensor-based glucose monitoring systems.

2. Data on file, Abbott Diabetes Care, Inc. 

3. Hilliard, M., et al. Diabetes Technology & Therapeutics. (2019). https:/doi.org/10.1089/dia.2019.0142.

4. Haak, T. Diabetes Therapy (2017). https://doi.org/10.1007/s13300-016-0223-6.

5. Alva, S. J Diabetes Sci Technol (2020): https://doi.org/10.1177%2F1932296820958754.

6. The views, opinions, and positions expressed by FreeStyle Libre systems users are theirs alone, and do not necessarily reflect the views, opinions, and positions of Abbott or any employee thereof. The views expressed should not be used for medical diagnosis or treatment or as a substitute for professional medical advice. Individual symptoms, situations and circumstances may vary.

7. Fokkert, M. BMJ Open Diab Res Care (2019). https://doi.org/10.1136/bmjdrc-2019-000809.

8. 60-minute warm-up required when applying the sensor.

9. Sensor is water resistant in up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.

10. Finger pricks are required if your glucose readings and alarms do not match symptoms or expectations

11. Among patient-applied sensors.

12. The FreeStyle LibreLink app is only compatible with certain mobile devices and operating systems. Please check the website for more information about device compatibility before using the app. Use of FreeStyle LibreLink requires registration with LibreView.

13. The FreeStyle Libre system apps are only compatible with certain mobile devices and operating systems. Please check the Support section of our website for more information about device compatibility before using the app. Use of the FreeStyle Libre system app requires registration with LibreView.

14. FreeStyle Libre, FreeStyle Libre 2 and FreeStyle Libre 3 systems are part of the same family of products.  

15. Data on file, Abbott Diabetes Care, Inc. Based on the reading frequency in Dexcom G7 CGM User Guide and Medtronic Guardian Connect System User Guide compared to readings every minute for FreeStyle Libre 2 and FreeStyle Libre 3 systems sensors.

16. Huang, E. Diabetes (2022). https://doi.org/10.2337/db22-73-LB.

17. Unger, J. Postgraduate Medicine (2020). https://doi.org/10.1080/00325481.2020.1744393.

18. Notifications will only be received when alarms are turned on and the sensor is within 6 meters unobstructed of the reading device.

19. All data transferred to LibreView is encrypted using industry-standard SSL/TLS to ensure that it remains private from malicious parties.

20. Campbell, F. M. Pediatric Diabetes (2018). https://doi.org/10.1111/pedi.12735. 

21. The LibreLinkUp app is only compatible with certain mobile devices and operating systems. Please check www.librelinkup.com for more information about device compatibility before using the app. Use of LibreLinkUp and FreeStyle Libre 2 app require registration with LibreView. The LibreLinkUp mobile app is not intended to be a primary glucose monitor: home users must consult their primary device(s) and consult a healthcare professional before making any medical interpretation and therapy adjustments from the information provided by the app

23. Data on file, Abbott Diabetes Care, Inc. Based on the signal strength in Dexcom G6 CGM User Guide and Medtronic Guardian Connect System User Guide.

24. The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.

25. The user’s device must have internet connectivity for glucose data to automatically upload to LibreView.

26. The user’s device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.

27. Evans, M. Diabetes Therapy (2022). https://doi.org/10.1007/s13300-022-01253-9.

28. Bolinder, J. The Lancet (2016). https://doi.org/10.1016/S0140-6736(16)31535-5.

30. FreeStyle Libre 2 User's Manual/Data on file, Abbott Diabetes Care. Inc.

32. Cengiz, Eda, and William V Tamborlane. “A Tale of Two Compartments: Interstitial Versus Blood Glucose Monitoring.” Diabetes Technology & Therapeutics 11, Suppl 1 (June 2009): S11-6. https://doi.org/10.1089/dia.2009.0002.

33. Based on comparison of list prices of the FreeStyle Libre portfolio versus competitor CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

34. The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.

37. Yaron, M. Diabetes Care (2019): https://doi.org/10.2337/dc18-0166. 

38. Leelarathna, L. New England Journal of Medicine (2022). https://doi.org/10.1056/nejmoa2205650.

39. Leading manufacturers include Accu-Chek, OneTouch and Ascencia.

40. Do not use during xylose absorption testing. Study conducted in 2009. Data on file, Abbott Diabetes Care Inc.

45. Glucose alarms will transfer to the LibreLinkUp app users when users are connected and alarms are enabled on FreeStyle Libre systems apps.

46. The FreeStyle Libre systems apps are designed to facilitate data sharing between patients and their healthcare providers and caregivers.

47. The FreeStyle Libre systems apps are designed to facilitate data sharing between patients and their healthcare providers and caregivers.

48. All data transferred to LibreLinkUp is encrypted using industry-standard SSL/TLS to ensure that it remains private from malicious parties

201. Plan coverage criteria may vary based on individual plan design. Talk to your insurance provider or your plan administrator to find out about your coverage eligibility. Plan members may also check their coverage on their insurer’s app/website. Data on file, Abbott Diabetes Care.

202. Bokma, Anne, Diabetes Canada. ”Distressed by Diabetes.” Accessed Mar. 13, 2023. https://www.diabetes.ca/about-diabetes/stories/distressed-by-diabetes-.

203. Centers for Disease Control and Prevention, “10 Tips for Coping with Diabetes Distress.” Accessed Mar. 13, 2023. https://www.cdc.gov/diabetes/articles/10-tips-coping-diabetes-distress.html

204. Centers for Disease Control and Prevention, “Diabetes and Mental Health.” Accessed Mar. 13, 2023. https://www.cdc.gov/diabetes/living-with/mental-health.html

205. Diabetes Canada, “Local Programs & Events.” (2023): Accessed Mar. 13, 2023. https://www.diabetes.ca/get-involved/local-programs---events?Region=&EventType=&SearchText=&Sort=&Page=.

207. The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Finger pricks are required if glucose readings and alarms do not match symptoms or expectations. The FreeStyle Libre 2 sensor communicates with the FreeStyle Libre 2 reader that started it or the FreeStyle Libre 2 app that started it. The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check the Compatibility Guide (PDF 69 KB) for more information about device compatibility before using the app. Use of FreeStyle Libre 2 requires registration with LibreView.

208. Diabetes Canada. Lifestyle Management. Diabetes Canada website. Accessed September 15, 2022. https://www.diabetes.ca/about-diabetes/lifestyle-management.

209. Diabetes Canada. Physical Activity. Diabetes Canada website. Accessed September 15, 2022. https://www.diabetes.ca/managing-my-diabetes/tools---resources/physical-activity.

210. The Canadian Society for Exercise Physiology (CSEP). The Canadian 24-Hour Movement Guidelines for Adults (18-64 years). CSEP website. Accessed September 15, 2022. https://csepguidelines.ca/guidelines/adults-18-64/.

211. Diabetes Canada. Maintaining Aerobic Exercise. Diabetes Canada website. Accessed September 15, 2022. https://www.diabetes.ca/DiabetesCanadaWebsite/media/Managing-My-Diabetes/Tools%20and%20Resources/maintaining-aerobic-exercise.pdf?ext=.pdf.

212. American Diabetes Association. Understanding A1C. American Diabetes Association website. Accessed December 7, 2022. https://www.diabetes.org/a1c.

213. Imran A, et al. 2018 clinical practice guidelines: targets for glycemic control. Can J Diabetes 2018;42(Suppl 1):S42-S46. https://doi.org/10.1016/j.jcjd.2017.10.030.

214. Diabetes Canada. Managing Your Blood Sugar. Diabetes Canada website. September 29, 2022. https://www.diabetes.ca/resources/tools---resources/managing-your-blood-sugar.

215. Punthakee Z, et al. Chapter 3: Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes 2018;42(Suppl 1):S10-S15.

216. Centers for Disease Control and Prevention (CDC). Diabetes Tests. CDC website. https://www.cdc.gov/diabetes/diabetes-testing/?CDC_AAref_Val=https://www.cdc.gov/diabetes/basics/getting-tested.html . Accessed July 11, 2023.

217. American Diabetes Association. A1C and eAG. American Diabetes Association website. Accessed December 7, 2022. https://www.diabetes.org/diabetes/a1c-test-meaning/a1c-and-eag.

218. Dunn T, et al. Development of the likelihood of low glucose (LLG) algorithm for evaluating risk of hypoglycemia: a new approach for using continuous glucose data to guide therapeutic decision making. J Diabetes Sci Technol 2014;8(4):720-730. https://doi.org/10.1177/1932296814532200.

219. Ajjan R, et al. Glucokinase MODY and implications for treatment goals of common forms of diabetes. Curr Diab Rep 2014;14(12):559-65. https://doi.org/10.1007/s11892-014-0559-0.

220. Rayman G. Glycaemic control, glucose variability and the triangle of diabetes care. Br J Diabetes 2016;16(Suppl 1):S3-S6. https://doi.org/10.15277/bjd.2016.070.

221. Lang J, et al. Expanded real-world use reaffirms strong correlation between scanning frequency of flash glucose monitoring and glucose control. Diabetes 2018;68(Suppl 1):972-P. https://doi.org/10.2337/db19-972-P.

222. Battelino T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42(8):1593-1603. https://doi.org/10.2337/dci19-0028.

223. Beck RW, et al. Validation of Time in Range as an outcome measure for diabetes clinical trials. Diabetes Care 2019;42(3): 400-405. https://doi.org/10.2337/dc18-1444.

224. Lu J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetes retinopathy in type 2 diabetes. Diabetes Care 2018;41(11):2370-2376. https://doi.org/10.2337/dc18-1131.

225. Frier BM, Heller SR, and McCrimmon R, eds. Hypoglycaemia in Clinical Diabetes. 3rd ed. Wiley Blackwell; 2014.

226. Diabetes Canada. Mild, Moderate or Severe Hypoglycemia - What’s the Difference? Diabetes Canada website. Accessed September 14, 2022. https://www.diabetes.ca/managing-my-diabetes/stories/mild,-moderate-or-severe-hypoglycemia---what-s-the-difference-.

227. Yale J-F, et al. 2018 clinical practice guidelines: hypoglycemia. Can J Diabetes 2018;42(Suppl 1):S104-S108. https://doi.org/10.1016/j.jcjd.2017.10.010.

228. Gold AE, et al. Hypoglycemia and non-cognitive aspects of psychological function in insulin-dependent (type 1) diabetes mellitus (IDDM). Diabet Med 1997;14(2):111-118. https://doi.org/10.1002/(SICI)1096-9136(199702)14:2%3C111::AID-DIA309%3E3.0.CO;2-S.

229. Rana O, et al. Acute hypoglycemia decreases myocardial blood flow reserve in patients with type 1 diabetes mellitus and in healthy humans. Circulation 2011;124(14):1548-56. https://doi.org/10.1161/CIRCULATIONAHA.110.992297.

230. Kedia N. Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. Diabetes Metab Syndr Obes 2011;4:337-346. http://dx.doi.org/10.2147/DMSO.S20633.

231. Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol 2014;10(12): 711-722. https://doi.org/10.1038/nrendo.2014.170.

232. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDKD). Low Blood Glucose (Hypoglycemia). NIDDKD website. Accessed September 14, 2022. https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia#likely.

233. Seaquist ER, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36(5):1384-1395. https://doi.org/10.2337/dc12-2480.

234. Inkster B, Frier BM. Diabetes and Driving. Diabetes Obesity Metab 2013;15(9):775-783. https://doi.org/10.1111/dom.12071.

235. Bolinder J, et al. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet 2016;388(10057):2254-2263. https://doi.org/10.1016/S0140-6736(16)31535-5.

236. Haak T, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8(1):55-73. https://doi.org/10.1007/s13300-016-0223-6.

237. Diabetes Canada. Coverage of Capillary Blood Glucose Monitoring (CBG) Strips. Diabetes Canada website. Accessed February 8, 2023. https://www.diabetes.ca/advocacy---policies/advocacy-reports/comparisons-by-province-territory/coverage-of-capillary-blood-glucose-monitoring-(cbg)-strips.

238. National Cancer Institute. Interstitial Fluid. National Institutes of Health website. Accessed February 8, 2023. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/interstitial-fluid.

239. Campbell FM, et al. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. Pediatr Diabetes 2018;19(7):1294-1301. https://doi.org/10.1111/pedi.12735.

241. The LibreView website is only compatible with certain operating systems and browsers. Please check www.libreview.com for additional information.

242. Data on file, Abbott Diabetes Care, Inc. Based on the number of users in Canada for the FreeStyle Libre portfolio compared to the number of users for other leading personal use sensor-based glucose monitoring systems.

243. Data on file, Abbott Diabetes Care, Abbott Laboratories Co. Based on the number of prescriptions claimed at pharmacy in Canada for the FreeStyle Libre portfolio compared to the number of prescriptions claimed at pharmacy for other leading sensor-based glucose monitoring systems.

244. Data on file, Abbott Diabetes Care, Abbott Laboratories Co. For patients with Type 1 or Type 2 diabetes. Plan coverage criteria may vary based on individual plan design. Talk to your insurance provider or your plan administrator to find out about your coverage eligibility. Plan members may also check their coverage on their insurer’s app/website.

245. Applies to Freestyle Libre users paying cash or those eligible for private insurance with out-of-pocket costs. Eligibility and savings amount may vary.

246. Non-Insured Health Benefits.